New drugs 07, part I.
In this article, you'll learn about 13 new drugs, including: insulin glulisine and insulin detemir, both human insulin analogues; ranolazine, the first drug approved to treat chronic angina in more than a decade; conivaptan HCl, the first drug approved to treat hyponatremia in patients with normal fluid balance. Unless otherwise specified, the information in the following summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breast-feeding. Also consult the package insert, a pharmacist, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions for all these drugs.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA, USA.
D000069594:Abatacept; D000083:Acetanilides / Q000627:therapeutic use; D000527:Alprostadil / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077612:Anidulafungin; D065092:Antidiuretic Hormone Receptor Antagonists; D000935:Antifungal Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001087:Arabinonucleosides / Q000627:therapeutic use; D001552:Benzazepines / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000627:therapeutic use; D017277:Drug Approval; D004347:Drug Interactions; D016903:Drug Monitoring; D004358:Drug Therapy / Q000451:nursing / Q000639:trends; D054714:Echinocandins; D005227:Fatty Acids / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D018796:Immunoconjugates / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007211:Indoles / Q000627:therapeutic use; D007328:Insulin / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting; D036341:Intercellular Signaling Peptides and Proteins / Q000627:therapeutic use; D000077269:Lenalidomide; D000068238:Lubiprostone; D009536:Niacinamide / Q000031:analogs & derivatives; D010353:Patient Education as Topic; D010456:Peptides, Cyclic / Q000627:therapeutic use; D010671:Phenylurea Compounds; D010879:Piperazines / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D000069458:Ranolazine; D000077157:Sorafenib; D000077210:Sunitinib; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States
D000083:Acetanilides; D065092:Antidiuretic Hormone Receptor Antagonists; D000935:Antifungal Agents; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D001552:Benzazepines; D001557:Benzenesulfonates; D054714:Echinocandins; D005227:Fatty Acids; D007004:Hypoglycemic Agents; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D007211:Indoles; D007328:Insulin; D049528:Insulin, Long-Acting; D036341:Intercellular Signaling Peptides and Proteins; D010456:Peptides, Cyclic; D010671:Phenylurea Compounds; D010879:Piperazines; D011725:Pyridines; D011758:Pyrroles; C065700:myotrophin; C106389:conivaptan; D009536:Niacinamide; D000069057:Insulin Detemir; D013792:Thalidomide; C104457:nelarabine; D000068238:Lubiprostone; D000069594:Abatacept; C479079:insulin glulisine; D000077612:Anidulafungin; D000077157:Sorafenib; D000069458:Ranolazine; D000077269:Lenalidomide; D000527:Alprostadil; D000077210:Sunitinib